Open AccessPlasma half‐lives and bioavailability of human monoclonal Rh D antibodies BRAD‐3 and BRAD‐5 following intramuscular injection into Rh D‐negative volunteers
Author(s) -
GOODRICK J.,
KUMPEL B.,
PAMPHILON D.,
FRASER I.,
CHAPMAN G.,
DAWES B.,
ANSTEE D.
Publication year - 1994
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1994.tb06600.x
Subject(s) - polyclonal antibodies , antibody , bioavailability , monoclonal antibody , immunology , intramuscular injection , chemistry , medicine , pharmacology
Summary Two human MoAbs, BRAD‐3 (an IgG3 anti‐D) and BRAD‐5 (an IgG1 anti‐D), were produced from Epstein‐Barr virus (EBV)‐transformed B lymphoblastoid cell lines grown in hollow fibre bioreactors. Six Rh D‐negative male volunteers were injected intramuscularly with anti‐D; two received BRAD‐3 (approx. 1500μg, 2600IU), two were given BRAD‐5 (300 μg, 2000 IU), and two had polyclonal anti‐D immunoglobulin (500IU, approx. 100μg anti‐D). Levels of anti‐D in plasma samples taken up to 42 days later were measured by a sensitive AutoAnalyser method. The half life of BRAD‐5 (mean 22·2 days) was greater, and that of BRAD‐3 (mean 10·2 days) less than that of polyclonal anti‐D (mean 15·6 days). The bioavailability (plasma uptake) of the MoAbs (mean 33·9%) was less than that of the polyclonal anti‐D (mean 60·3%). BRAD‐3 and BRAD‐5 may be suitable for use in antenatal and post‐natal prophylaxis against Rh D haemolytic disease of the newborn.